Literature DB >> 25566741

Factors Associated with Uptake of Genetics Services for Hypertrophic Cardiomyopathy.

Amirah Khouzam1, Andrea Kwan1,2, Samantha Baxter3, Jonathan A Bernstein4.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a common cardiovascular disorder with variable expressivity and incomplete penetrance. Clinical guidelines recommend consultation with a genetics professional as part of an initial assessment for HCM, yet there remains an underutilization of genetics services. We conducted a study to assess factors associated with this underutilization within the framework of the Health Belief Model (HBM). An online survey was completed by 306 affected individuals and at risk family members. Thirty-seven percent of individuals (113/306) had visited a genetics professional for reasons related to HCM. Genetic testing was performed on 53 % (162/306). Individuals who had undergone testing were more likely to have seen a genetics professional (p < 0.001), had relatives with an HCM diagnosis (p = 0.002), and have a known familial mutation (p < 0.001). They were also more likely to agree that genetic testing would satisfy their curiosity (p < 0.001), provide reassurance (p < 0.001), aid family members in making healthcare decisions (p < 0.001), and encourage them to engage in a healthier lifestyle (p = 0.002). The HBM components of cues to action and perceived benefits and barriers had the greatest impact on uptake of genetic testing. In order to ensure optimal counseling and care for individuals and families with HCM, awareness and education around HCM and genetic services should be promoted in both physicians and patients alike.

Entities:  

Keywords:  Genetic services; Genetic testing; Health Belief Model; Hypertrophic cardiomyopathy (HCM); Utilization

Mesh:

Year:  2015        PMID: 25566741     DOI: 10.1007/s10897-014-9810-8

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  29 in total

1.  Factors influencing intention to obtain a genetic test for colon cancer risk: a population-based study.

Authors:  Janice Yanushka Bunn; Kwadwo Bosompra; Takamaru Ashikaga; Brian S Flynn; John K Worden
Journal:  Prev Med       Date:  2002-06       Impact factor: 4.018

2.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

Review 3.  Use and interpretation of genetic tests in cardiovascular genetics.

Authors:  Colleen Caleshu; Sharlene Day; Heidi L Rehm; Samantha Baxter
Journal:  Heart       Date:  2010-10       Impact factor: 5.994

Review 4.  Hypertrophic cardiomyopathy in 2012.

Authors:  Carolyn Y Ho
Journal:  Circulation       Date:  2012-03-20       Impact factor: 29.690

5.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy.

Authors:  Iacopo Olivotto; Martin S Maron; A Selcuk Adabag; Susan A Casey; Daniela Vargiu; Mark S Link; James E Udelson; Franco Cecchi; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

6.  Underutilization of genetics services for autism: the importance of parental awareness and provider recommendation.

Authors:  Kimberly Vande Wydeven; Andrea Kwan; Antonio Y Hardan; Jonathan A Bernstein
Journal:  J Genet Couns       Date:  2012-03-14       Impact factor: 2.537

7.  Efficacy of the health belief model for predicting intention to pursue genetic testing for colorectal cancer.

Authors:  Amanda Cyr; Tim Allen Dunnagan; George Haynes
Journal:  J Genet Couns       Date:  2009-11-10       Impact factor: 2.537

8.  Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy.

Authors:  Imke Christiaans; Erwin Birnie; Gouke J Bonsel; Arthur Am Wilde; Irene M van Langen
Journal:  Eur J Hum Genet       Date:  2008-05-14       Impact factor: 4.246

9.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.

Authors:  Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin
Journal:  J Card Fail       Date:  2009-03       Impact factor: 5.712

10.  Knowledge and attitudes towards genetic testing: a two year follow-up study in patients with asthma, diabetes mellitus and cardiovascular disease.

Authors:  Hiske Calsbeek; Mattijn Morren; Jozien Bensing; Mieke Rijken
Journal:  J Genet Couns       Date:  2007-02-23       Impact factor: 2.537

View more
  5 in total

Review 1.  Genetics of paediatric cardiomyopathies.

Authors:  Stephanie M Ware
Journal:  Curr Opin Pediatr       Date:  2017-10       Impact factor: 2.856

2.  Uptake of Predictive Genetic Testing and Cardiac Evaluation for Children at Risk for an Inherited Arrhythmia or Cardiomyopathy.

Authors:  Susan Christian; Joseph Atallah; Robin Clegg; Michael Giuffre; Cathleen Huculak; Tara Dzwiniel; Jillian Parboosingh; Sherryl Taylor; Martin Somerville
Journal:  J Genet Couns       Date:  2017-07-11       Impact factor: 2.537

3.  Perceptions of genetic variant reclassification in patients with inherited cardiac disease.

Authors:  Eugene K Wong; Kirsten Bartels; Julie Hathaway; Charlotte Burns; Laura Yeates; Christopher Semsarian; Andrew D Krahn; Alice Virani; Jodie Ingles
Journal:  Eur J Hum Genet       Date:  2019-03-21       Impact factor: 4.246

Review 4.  A Person-Centered Approach to Cardiovascular Genetic Testing.

Authors:  Julia Platt
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

5.  Health screening behaviors among adults with hereditary hemorrhagic telangiectasia in North America.

Authors:  Melanie Baxter; Lori Erby; Debra Roter; Barbara A Bernhardt; Peter Terry; Alan Guttmacher
Journal:  Genet Med       Date:  2016-10-13       Impact factor: 8.822

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.